OncoCyte Corporation OCX
At closeJun 17, 2025, 4:00 PM EDT
52-week range unavailable
- YTD
- +34.45%
- 1 year
- +15.94%
- Market cap
- 36.87M
- Revenue (ttm)
- 709.00K
- Shares out
- 16.84M
- Forward P/E
- -1.27
- YTD return
- +34.45%
- 1-year return
- +15.94%
- Volume
- 100.56K
- Open
- 2.82
- Previous close
- 3.20
- Day's range
- 2.82 – 3.20
- Price target
- 4.13 (+28.9%)
- Earnings date
- Mar 29, 2024
2Y -1.57 (-36.51%)
Key statistics
- Enterprise value
- 30.66M
- PEG ratio
- 0.00
- Price / sales
- 52.00
- Price / book
- 3.09
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -73.20%
- Free cash flow
- -7.61M
- Total cash
- 3.36M
- Total debt
- 3.99M
- Return on equity
- -165.32%
- Short % of float
- 1.88%
- 50-day average
- 2.73
- 200-day average
- 2.89
Analyst view
- Target (low)
- 4.00
- Target (mean)
- 4.13
- Target (high)
- 4.25
- Strong buy1
- Buy0
- Hold2
- Sell0
- Strong sell0
Next earnings
Mar 29, 2024
Expected Mar 29, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | 0.00 | -0.98 | — | — |
| Aug 8, 2024 | Jun 1, 2024 | 0.00 | -0.36 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -1.13 | — | — |
| Mar 29, 2024 | Dec 1, 2023 | -1.57 | — | — | — |
| Nov 9, 2023 | Sep 1, 2023 | -1.52 | -0.57 | +0.95 | +62.50% |
| Aug 10, 2023 | Jun 1, 2023 | -2.60 | -1.07 | +1.53 | +58.85% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 9, 2024 | Needham | reit | Buy | Buy |
| May 16, 2024 | Needham | reit | Buy | Buy |
| Apr 24, 2024 | Needham | main | Buy | Buy |
| Apr 17, 2024 | Stephens & Co. | reit | Equal-Weight | Equal-Weight |
| Apr 15, 2024 | Benchmark | reit | Speculative Buy | Speculative Buy |
| Nov 13, 2023 | Piper Sandler | main | Neutral | Neutral |
About OncoCyte Corporation
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- oncocyte.com
News
Oncocyte Eyes Faster, Less Invasive Heart Transplant Rejection Testing 
Oncocyte Q2 Earnings Call Highlights 
Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville 
Medicare Boosts Reimbursement for Oncocyte's Flagship Technology 
OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript 
Oncocyte Reports Q1 2025 Results and Business Progress 
Earnings Scheduled For May 12, 2025 
Oncocyte to Release First Quarter 2025 Results on May 12, 2025 
Oncocyte to Release First Quarter 2025 Results on May 12, 2025 
Best Momentum Stocks to Buy for May 6th
Your note
Sign in to keep a note on OCX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARNO ANDREW | Director | Purchase | Apr 10, 2024 | 84,662 |
| BROADWOOD PARTNERS, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 1, 2024 | 0 |
| GUTFREUND JOHN PETER | Director | Stock Award(Grant) | Apr 2, 2023 | 0 |
| JAMES ANDREA S. | Chief Financial Officer | Purchase | Dec 4, 2024 | 53,670 |
| KINGSLEY ALFRED D | Director | Stock Award(Grant) | Jun 22, 2023 | 583,223 |
| LAST ANDREW J | Director | Stock Award(Grant) | Jun 22, 2023 | 90,170 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Broadwood Capital, Inc. | 29.28% | 4,929,066 | 10.79M | Sep 29, 2024 |
| AWM Investment Company, Inc. | 6.52% | 1,097,175 | 2.40M | Sep 29, 2024 |
| Pura Vida Investments, Llc | 2.94% | 495,345 | 1.08M | Sep 29, 2024 |
| Vanguard Group Inc | 1.46% | 245,388 | 537.40K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.62% | 103,980 | 227.72K | Sep 29, 2024 |
| Blackrock Inc. | 0.47% | 79,833 | 174.83K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.92% | 154,885 | 339.20K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.50% | 84,999 | 186.15K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.40% | 67,344 | 147.48K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.11% | 18,032 | 39.49K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.09% | 14,756 | 32.31K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.08% | 13,836 | 30.30K | Oct 30, 2024 |